Are tranexamic acid and-aminocaproic acid adequate substitutes for aprotinin

Annals of Cardiac Anaesthesia

Volumn 15, Issue 1, 2012, Pages 4-5

  Tempe, Deepak K ^a   Hasija, Suruchi ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMINOCAPROIC ACID; APROTININ; CREATININE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

BLEEDING; BLOOD TRANSFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EDITORIAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRAOPERATIVE PERIOD; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MORTALITY; NEUROPROTECTION; POSTOPERATIVE PERIOD; PUBLICATION; RISK BENEFIT ANALYSIS; SEIZURE; FEMALE; HEART SURGERY; MALE; NOTE; POSTOPERATIVE COMPLICATION;

ANTIFIBRINOLYTIC AGENTS; CARDIAC SURGICAL PROCEDURES; FEMALE; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; SEIZURES; TRANEXAMIC ACID;

EID: 84856845734     PISSN: 09719784     EISSN: 09745181     Source Type: Journal    
DOI: 10.4103/0971-9784.91465     Document Type: Editorial

References (16)

1. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, et al: 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists. Blood conservation clinical practice guidelines. Ann Thorac Surg 91:944-82, 2011.
2. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115:2801-13. (Pubitemid 46876483)
3. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31. (Pubitemid 351749156)
4. Montes FR, Pardo DF, Carreño M, Arciniegas C, Dennis RJ, Umaña JP. Risk factors associated with postoperative seizures in patients undergoing cardiac surgery who received tranexamic acid: A case-control study. Ann Card Anaesth 2012;15:6-12.
5. Murkin JM, Falter F, Grantan J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010;110:350-3.
6. Martin K, Knorr J, Breuer T, Gertler R, Macguill M, Lange R, et al. Seizures after open heart surgery: comparison of e-aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth 2011;25:20-5.
7. Furtmüller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid (A) receptor antagonistic effect. J Pharmacol Exp Ther 2002;301:168-73. (Pubitemid 34256345)
8. Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, et al. A comparison before and after aprotinin was supended in cardiac surgery: Different results in the real world from a single cardiac center in China. J Thorac Cardiovasc Surg 2009;138:897-903.
9. Sniecinski RM, Chen EP, Makadia SS, Kikura M, Bolliger D, Tanaka KA. Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest. J Cardiothorac Vasc Anesth 2010;24:959-63.
10. Martin K, Gertler R, Liermann H, Mayr NP, Macguill M, Schreiber C, et al. Switch from aprotinin to {varepsilon}-aminocaproic acid: impact on blood loss, transfusion, and clinical outcome in neonates undergoing cardiac surgery. Br J Anaesth 2011;107:934-9.
11. DeSantis SM, Toole JM, Kratz JM, Uber WE, Wheat MJ, Stroud MR, et al. Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation 2011;124:S62-9.
12. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008;107:1783-90.
13. Ishibashi N, Iwata Y, Zurakowski D, Lidov HG, Jonas RA. Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass. Perfusion 2009;24:99-105.
14. McMullan V, Alston RP. The effect of the suspension of the license for aprotinin on the care of patients undergoing cardiac surgery: a survey of cardiac anesthesiologists' and surgeons' opinions in the united kingdom. J Cardiothorac Vasc Anesth 2010;24:418-21.
15. Spiess BD. Pro: The practice of cardiac anesthesia has changed after the withdrawal of aprotinin. J Cardiothorac Vasc Anesth 2010;24:875-8.
16. Beattie WS, Karkouti K. The post-BART anti-fibrinolytic dilemma? J Cardiothorac Vasc Anesth 2011;25:3-5.